PK/PD analysis of methotrexate in the rheumatic treatment made use of genetic polymorphism of drug delivery protein and clinical development

PK/PD analysis of methotrexate in the rheumatic treatment made use of genetic polymorphism of drug delivery protein and clinical development - PK/PD analysis of methotrexate in the rheumatic treatment and clinical development

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001609

Enrollment

300

Registered

2008-12-30

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.20-70 years old men and women. 2.The patient who has articular rheumatism diagnosed by classification standard in 1987 of American rheumatic society (ACR). 3.The patient who does not have history of previous of MTX medication and needs MTX treatment. 4.The patient who takes MTX more than 5mg in a week.

Exclusion criteria

Exclusion criteria: 1.History of severe circulatory disease, hepatic disorder,renal disease, digestive system disease, blood disorder, interstitial pneumonia. 2.The patient which treatment of RA is no good. 3.The patient having therapeutic experience of surgical remedy for RA during study participation. 4.A pregnant woman, nursing mother, a person who hope for the pregnancy all over the study period.

Design outcomes

Primary

Measure	Time frame
Genetic polymorphism Expression of protein Concentration of Methotrexate in blood DAS28	—

Countries

Japan

Contacts

Public ContactTakuya Morimoto

Oita University Hospital Clinical pharmacology center

morimott@med.oita-u.ac.jp097-586-5952

Outcome results